Latest News about GSK
Recent news which mentions GSK
JNJ Terminates NASH Program Pact With Arrowhead Pharmaceuticals
February 15, 2023
From Benzinga
Vir Biotech To Work On Next-Gen COVID-19 Solutions Independently, Or With Other Partners, As GSK Walks Out
February 14, 2023
From Benzinga
FDA AdComm Votes In Favor Of GSK's Jemperli Single Arm Trial Plan For Rectal Cancer Setting
February 10, 2023
Tickers
GSK
From Benzinga
FDA Grants Complete Approval For GSK's Jemperli For Endometrial Cancer
February 10, 2023
Tickers
GSK
From Benzinga
Earnings Scheduled For February 1, 2023
February 01, 2023
From Benzinga
GSK posts higher sales and profit of $1.85 billion, lifted by specialty medicines and vaccines businesses
February 01, 2023
Tickers
GSK
From MarketWatch
From Benzinga
CureVac Shares Pop After Encouraging Update From COVID-19, Flu mRNA Vaccine Programs
January 30, 2023
From Benzinga
3 Penny Stocks That Could Make You Filthy Rich
January 25, 2023
From Motley Fool
From Benzinga
From Motley Fool
From Benzinga
Moderna Gets A 'Booster' Shot: Why Stock Is Up Nearly 7% Today
January 18, 2023
From Benzinga
Moderna, CureVac and Ocugen offer updates on COVID vaccines, while China cracks down on critics of government’s pandemic response
January 09, 2023
From MarketWatch
From InvestorPlace
GSK Looking For Under-Appreciated M&A Targets, Not Trying To Be Next Roche Or AstraZeneca
December 30, 2022
From Benzinga
7 Drug Stocks That Will Soar in 2023
December 22, 2022
From InvestorPlace
2 Smartest Tech Stocks to Buy in 2022 and Beyond
December 20, 2022
From Motley Fool
Comparing With Pfizer's Vaccine, Icosavax RSV Candidate 'Could Establish Differentiation,' Analyst Says
December 14, 2022
From Benzinga
Options Trader Betting On GSK Stock Rising Heading Into 2023
December 13, 2022
Tickers
GSK
From Benzinga
Wave Life Sciences Shares Move Higher On Therapeutic Pact With GSK Targeting Genetic Disorders
December 13, 2022
From Benzinga
France Health Body Advises Unfavorable Opinion Regarding Valneva's COVID-19 Vaccine
December 08, 2022
From Benzinga
GSK's Jemperli/Chemo Combo Shows Response Rate Of 46% In Head-To-Head Lung Cancer Trial
December 07, 2022
From Benzinga
From Benzinga
From Benzinga
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
